Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1810 results
June 2017
-
Media ReleaseSandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseasesEuropean Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare…
-
Media ReleaseNovartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their diseaseLarge-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease These new data underscore the disconnect between self-…
-
Media ReleaseFDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus® Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference…
-
Media ReleaseNovartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 yearsCosentyx® is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] Additional data…
-
Media ReleaseNovartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual MeetingData from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month AMG 334 (erenumab)…
-
Media ReleaseNovartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCLAt interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43%…
-
Women in Science: Shilpa Shah-Mehta
-
Media ReleaseNovartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product labelTasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials…
-
Media ReleaseNovartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancerPhase I/II study to evaluate Mekinist® (trametinib) in combination with Opdivo® (nivolumab) and Opdivo + Yervoy® (ipilimumab) Collaboration expands upon existing clinical investigation of…
-
Media ReleaseNovartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancerCollaboration will use real-world patient data and cognitive computing with aim of improving outcomes in advanced breast cancer Brings Novartis innovation and breast cancer expertise together with…
-
Media ReleaseNovartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanomaStudy is longest follow-up to date of a BRAF and MEK inhibitor combination therapy in patients with BRAF V600-mutant metastatic melanoma[1] Study shows stable overall survival and progression-free…
-
Innovating on a trusted class of antibiotics to attack superbugs
A new compound aims to attack dangerous antibiotic-resistant bacteria.
Pagination
- ‹ Previous page
- 1
- …
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- …
- 151
- › Next page